Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 171

1.

Endocrine and haemodynamic changes in resistant hypertension, and blood pressure responses to spironolactone or amiloride: the PATHWAY-2 mechanisms substudies.

Williams B, MacDonald TM, Morant SV, Webb DJ, Sever P, McInnes GT, Ford I, Cruickshank JK, Caulfield MJ, Padmanabhan S, Mackenzie IS, Salsbury J, Brown MJ; British Hypertension Society programme of Prevention And Treatment of Hypertension With Algorithm based Therapy (PATHWAY) Study Group.

Lancet Diabetes Endocrinol. 2018 Jun;6(6):464-475. doi: 10.1016/S2213-8587(18)30071-8. Epub 2018 Apr 11. Erratum in: Lancet Diabetes Endocrinol. 2018 Aug;6(8):e16.

2.

Microalbuminuria in subjects with hypertension attending specialist blood pressure clinics.

Alharf AA, Cleland S, Webster J, McInnes GT, Padmanabhan S.

J Hum Hypertens. 2016 Sep;30(9):527-33. doi: 10.1038/jhh.2015.116. Epub 2015 Dec 17.

PMID:
26674756
3.

Contrasting mortality risks among subgroups of treated hypertensive patients developing new-onset diabetes.

Lip S, Jeemon P, McCallum L, Dominiczak AF, McInnes GT, Padmanabhan S.

Eur Heart J. 2016 Mar 21;37(12):968-74. doi: 10.1093/eurheartj/ehv557. Epub 2015 Oct 27.

4.

Acetaminophen use and risk of myocardial infarction and stroke in a hypertensive cohort.

Fulton RL, Walters MR, Morton R, Touyz RM, Dominiczak AF, Morrison DS, Padmanabhan S, Meredith PA, McInnes GT, Dawson J.

Hypertension. 2015 May;65(5):1008-14. doi: 10.1161/HYPERTENSIONAHA.114.04945. Epub 2015 Mar 23.

PMID:
25801870
5.

Response to Effect of serum chloride on mortality in hypertensive patients.

McCallum L, Jeemon P, Hastie CE, Patel RK, Williamson C, Redzuan AM, Dawson J, Sloan W, Muir S, Morrison D, McInnes GT, Freel EM, Walters M, Dominiczak AF, Sattar N, Padmanabhan S.

Hypertension. 2014 Mar;63(3):e15. No abstract available.

PMID:
24678524
6.

Serum chloride is an independent predictor of mortality in hypertensive patients.

McCallum L, Jeemon P, Hastie CE, Patel RK, Williamson C, Redzuan AM, Dawson J, Sloan W, Muir S, Morrison D, McInnes GT, Freel EM, Walters M, Dominiczak AF, Sattar N, Padmanabhan S.

Hypertension. 2013 Nov;62(5):836-43. doi: 10.1161/HYPERTENSIONAHA.113.01793. Epub 2013 Aug 26. Erratum in: Hypertension. 2014 Feb;63(2):e11.

PMID:
23980073
7.

Long-term and ultra long-term blood pressure variability during follow-up and mortality in 14,522 patients with hypertension.

Hastie CE, Jeemon P, Coleman H, McCallum L, Patel R, Dawson J, Sloan W, Meredith P, Jones GC, Muir S, Walters M, Dominiczak AF, Morrison D, McInnes GT, Padmanabhan S.

Hypertension. 2013 Oct;62(4):698-705. doi: 10.1161/HYPERTENSIONAHA.113.01343. Epub 2013 Aug 19.

PMID:
23959561
8.

Noninvasive cardiac event monitoring to detect atrial fibrillation after ischemic stroke: a randomized, controlled trial.

Higgins P, MacFarlane PW, Dawson J, McInnes GT, Langhorne P, Lees KR.

Stroke. 2013 Sep;44(9):2525-31. doi: 10.1161/STROKEAHA.113.001927. Epub 2013 Jul 30.

PMID:
23899913
9.

Blood pressure response to patterns of weather fluctuations and effect on mortality.

Aubinière-Robb L, Jeemon P, Hastie CE, Patel RK, McCallum L, Morrison D, Walters M, Dawson J, Sloan W, Muir S, Dominiczak AF, McInnes GT, Padmanabhan S.

Hypertension. 2013 Jul;62(1):190-6. doi: 10.1161/HYPERTENSIONAHA.111.00686. Epub 2013 May 6.

PMID:
23648702
10.

Acetaminophen use and change in blood pressure in a hypertensive population.

Dawson J, Fulton R, McInnes GT, Morton R, Morrison D, Padmanabhan S, Hewitt J, Meredith P, Muir S, Dominiczak AF, Walters MR.

J Hypertens. 2013 Jul;31(7):1485-90; discussion 1490. doi: 10.1097/HJH.0b013e328360f6f8.

PMID:
23588196
11.

Cardiovascular outcomes in hypertensive patients: comparing single-agent therapy with combination therapy.

Weber MA, Julius S, Kjeldsen SE, Jia Y, Brunner HR, Zappe DH, Hua TA, McInnes GT, Schork A, Mancia G, Zanchetti A.

J Hypertens. 2012 Nov;30(11):2213-22. doi: 10.1097/HJH.0b013e3283582ed6.

PMID:
23011525
12.

Hematocrit predicts long-term mortality in a nonlinear and sex-specific manner in hypertensive adults.

Paul L, Jeemon P, Hewitt J, McCallum L, Higgins P, Walters M, McClure J, Dawson J, Meredith P, Jones GC, Muir S, Dominiczak AF, Lowe G, McInnes GT, Padmanabhan S.

Hypertension. 2012 Sep;60(3):631-8. doi: 10.1161/HYPERTENSIONAHA.112.191510. Epub 2012 Jul 16.

PMID:
22802225
13.

Usefulness of heart rate to predict cardiac events in treated patients with high-risk systemic hypertension.

Julius S, Palatini P, Kjeldsen SE, Zanchetti A, Weber MA, McInnes GT, Brunner HR, Mancia G, Schork MA, Hua TA, Holzhauer B, Zappe D, Majahalme S, Jamerson K, Koylan N.

Am J Cardiol. 2012 Mar 1;109(5):685-92. doi: 10.1016/j.amjcard.2011.10.025. Epub 2011 Dec 9.

PMID:
22169130
14.

Direct-acting vasodilators.

Cohn JN, McInnes GT, Shepherd AM.

J Clin Hypertens (Greenwich). 2011 Sep;13(9):690-2. doi: 10.1111/j.1751-7176.2011.00507.x. Epub 2011 Jul 18. Review.

15.

Long-term outcome following attendance at a transient ischemic attack clinic.

Cameron AC, Dawson J, Quinn TJ, Walters MR, McInnes GT, Morrison D, Sloan W, Lees KR.

Int J Stroke. 2011 Aug;6(4):306-11. doi: 10.1111/j.1747-4949.2011.00591.x. Epub 2011 Mar 16.

PMID:
21609417
16.

A double-blind, randomized study comparing the antihypertensive effect of eplerenone and spironolactone in patients with hypertension and evidence of primary aldosteronism.

Parthasarathy HK, Ménard J, White WB, Young WF Jr, Williams GH, Williams B, Ruilope LM, McInnes GT, Connell JM, MacDonald TM.

J Hypertens. 2011 May;29(5):980-90. doi: 10.1097/HJH.0b013e3283455ca5.

PMID:
21451421
17.

The effect of antihypertensive agents in people at high risk of cardiovascular disease and diabetes: a view through smoke and mirrors.

McInnes GT.

J Hum Hypertens. 2011 Jun;25(6):343-5. doi: 10.1038/jhh.2011.12. Epub 2011 Mar 10. No abstract available.

PMID:
21390054
18.

Do we need more long-term outcome trials for the treatment of hypertension?

Beevers DG, McInnes GT.

J R Coll Physicians Edinb. 2011 Mar;41(1):30-7. doi: 10.4997/JRCPE.2011.109.

PMID:
21365065
19.

Aliskiren and the calcium channel blocker amlodipine combination as an initial treatment strategy for hypertension control (ACCELERATE): a randomised, parallel-group trial.

Brown MJ, McInnes GT, Papst CC, Zhang J, MacDonald TM.

Lancet. 2011 Jan 22;377(9762):312-20. doi: 10.1016/S0140-6736(10)62003-X. Epub 2011 Jan 12.

PMID:
21236483
20.

Angiotensin-receptor blockade, cancer, and concerns.

Meredith PA, McInnes GT.

Lancet Oncol. 2010 Sep;11(9):819; author reply 821-2. doi: 10.1016/S1470-2045(10)70163-7. No abstract available.

PMID:
20816377
21.

Overtime is bad for the heart.

McInnes GT.

Eur Heart J. 2010 Jul;31(14):1672-3. doi: 10.1093/eurheartj/ehq116. Epub 2010 May 11. No abstract available.

PMID:
20460390
22.

Resting heart rate pattern during follow-up and mortality in hypertensive patients.

Paul L, Hastie CE, Li WS, Harrow C, Muir S, Connell JM, Dominiczak AF, McInnes GT, Padmanabhan S.

Hypertension. 2010 Feb;55(2):567-74. doi: 10.1161/HYPERTENSIONAHA.109.144808. Epub 2009 Dec 28.

PMID:
20038750
23.

Comparison of the efficacy of candesartan and losartan: a meta-analysis of trials in the treatment of hypertension.

Meredith PA, Murray LS, McInnes GT.

J Hum Hypertens. 2010 Aug;24(8):525-31. doi: 10.1038/jhh.2009.99. Epub 2009 Dec 17.

PMID:
20016523
24.

Does the ratio of serum aldosterone to plasma renin activity predict the efficacy of diuretics in hypertension? Results of RENALDO.

Parthasarathy HK, Alhashmi K, McMahon AD, Struthers AD, McInnes GT, Ford I, Connell JM, MacDonald TM.

J Hypertens. 2010 Jan;28(1):170-7. doi: 10.1097/HJH.0b013e328332b79b.

PMID:
20009770
25.

Drug treatment of prehypertension: Not now, not ever?

McInnes GT.

Blood Press. 2009;18(6):304-7. doi: 10.3109/08037050903416436.

PMID:
20001653
26.

The unintended consequences of clinical trials regulations.

McMahon AD, Conway DI, Macdonald TM, McInnes GT.

PLoS Med. 2009 Nov;3(11):e1000131. doi: 10.1371/journal.pmed.1000131. Epub 2009 Nov 17.

27.

Risks of socioeconomic deprivation on mortality in hypertensive patients.

Stewart L, McInnes GT, Murray L, Sloan B, Walters MR, Morton R, Padmanabhan S, Reid JL, Morrison DS.

J Hypertens. 2009 Apr;27(4):730-5. doi: 10.1097/HJH.0b013e328324ed58.

PMID:
19516172
28.

The UK's NHS and pharma: need for more clinical pharmacologists.

Aronson JK, Barnett DB, Breckenridge AM, Ferner RE, Jackson P, Maxwell SR, McInnes GT, Rawlins MD, Ritter JM, Routledge P, Walley TJ, Webb DJ, Williams D, Woods KL.

Lancet. 2009 Apr 11;373(9671):1251-2. doi: 10.1016/S0140-6736(09)60726-1. No abstract available.

PMID:
19362673
29.

Telmisartan to prevent recurrent stroke: the PRoFESS study: was the baby thrown out with the bathwater?

McInnes GT.

Stroke. 2009 May;40(5):1938-40. doi: 10.1161/STROKEAHA.108.541276. Epub 2008 Nov 26. No abstract available.

PMID:
19038906
30.

The Anglo-Scandinavian Cardiac Outcomes Trial: blood pressure-lowering limb: effects in patients with type II diabetes.

Ostergren J, Poulter NR, Sever PS, Dahlöf B, Wedel H, Beevers G, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E; ASCOT investigators.

J Hypertens. 2008 Nov;26(11):2103-11. doi: 10.1097/HJH.0b013e328310e0d9.

PMID:
18854748
31.

Progressive effects of valsartan compared with amlodipine in prevention of diabetes according to categories of diabetogenic risk in hypertensive patients: the VALUE trial.

Kjeldsen SE, McInnes GT, Mancia G, Hua TA, Julius S, Weber MA, Coca A, Girerd X, Jamerson K, Larochelle P, Macdonald T, Schmieder RE, Anthony Schork M, Viskoper R, Widimsky J, Zanchetti A.

Blood Press. 2008;17(3):170-7. doi: 10.1080/08037050802169644.

PMID:
18608200
32.

Reduced incidence of new-onset atrial fibrillation with angiotensin II receptor blockade: the VALUE trial.

Schmieder RE, Kjeldsen SE, Julius S, McInnes GT, Zanchetti A, Hua TA; VALUE Trial Group.

J Hypertens. 2008 Mar;26(3):403-11. doi: 10.1097/HJH.0b013e3282f35c67.

PMID:
18300848
33.

Drug Insight: eplerenone, a mineralocorticoid-receptor antagonist.

McManus F, McInnes GT, Connell JM.

Nat Clin Pract Endocrinol Metab. 2008 Jan;4(1):44-52. Review.

PMID:
18084345
34.

The relationships between initial blood pressure and the response to different antihypertensive agents.

Meredith PA, Murray LS, McInnes GT.

J Hypertens. 2007 Dec;25(12):2513-4; author reply 2514. No abstract available.

PMID:
17984676
35.

Antihypertensive drugs in combination: additive or greater than additive?

McInnes GT.

J Hum Hypertens. 2007 Dec;21(12):914-6. Epub 2007 Aug 16. No abstract available.

PMID:
17700727
36.

Prediction of cardiovascular outcome by estimated glomerular filtration rate and estimated creatinine clearance in the high-risk hypertension population of the VALUE trial.

Ruilope LM, Zanchetti A, Julius S, McInnes GT, Segura J, Stolt P, Hua TA, Weber MA, Jamerson K; VALUE Investigators.

J Hypertens. 2007 Jul;25(7):1473-9.

PMID:
17563571
37.

Renin inhibition: the holy grail of renin-angiotensin system blockade?

McInnes GT.

J Hum Hypertens. 2007 Oct;21(10):766-9. Epub 2007 May 31. No abstract available.

PMID:
17541389
38.

Does the aldosterone:renin ratio predict the efficacy of spironolactone over bendroflumethiazide in hypertension? A clinical trial protocol for RENALDO (RENin-ALDOsterone) study.

Parthasarathy HK, Alhashmi K, McMahon AD, Struthers AD, Connell JM, McInnes GT, Ford I, MacDonald TM.

BMC Cardiovasc Disord. 2007 May 9;7:14.

39.

What is the true place of blood pressure in cardiovascular risk management?

McInnes GT.

J Hypertens. 2007 May;25(5):925-8. No abstract available.

PMID:
17414651
40.

Saving lives: long-term morbidity and mortality trials with selective angiotensin receptor blocker therapy.

McInnes GT.

J Renin Angiotensin Aldosterone Syst. 2000 Jun;1(2 Suppl):S17-20. Review.

PMID:
17199214
41.

Outcomes in subgroups of hypertensive patients treated with regimens based on valsartan and amlodipine: An analysis of findings from the VALUE trial.

Zanchetti A, Julius S, Kjeldsen S, McInnes GT, Hua T, Weber M, Laragh JH, Plat F, Battegay E, Calvo-Vargas C, Cieśliński A, Degaute JP, Holwerda NJ, Kobalava J, Pedersen OL, Rudyatmoko FP, Siamopoulos KC, Störset O.

J Hypertens. 2006 Nov;24(11):2163-8.

PMID:
17053536
42.

Influence of a single dose of 20 mg tadalafil, a phosphodiesterase 5 inhibitor, on ambulatory blood pressure in subjects with hypertension.

Patterson D, McInnes GT, Webster J, Mitchell MM, Macdonald TM.

Br J Clin Pharmacol. 2006 Sep;62(3):280-7.

43.

The Valsartan Antihypertensive Long-Term Use Evaluation (VALUE) trial: outcomes in patients receiving monotherapy.

Julius S, Weber MA, Kjeldsen SE, McInnes GT, Zanchetti A, Brunner HR, Laragh J, Schork MA, Hua TA, Amerena J, Balazovjech I, Cassel G, Herczeg B, Koylan N, Magometschnigg D, Majahalme S, Martinez F, Oigman W, Seabra Gomes R, Zhu JR.

Hypertension. 2006 Sep;48(3):385-91. Epub 2006 Jul 24.

PMID:
16864741
44.

Effects of valsartan compared to amlodipine on preventing type 2 diabetes in high-risk hypertensive patients: the VALUE trial.

Kjeldsen SE, Julius S, Mancia G, McInnes GT, Hua T, Weber MA, Coca A, Ekman S, Girerd X, Jamerson K, Larochelle P, MacDonald TM, Schmieder RE, Schork MA, Stolt P, Viskoper R, Widimský J, Zanchetti A; VALUE Trial Investigators.

J Hypertens. 2006 Jul;24(7):1405-12.

PMID:
16794491
45.

Antioxidants and hypertension: another false dawn?

McInnes GT.

J Hypertens. 2005 Nov;23(11):1963-6. No abstract available.

PMID:
16208135
46.

Role of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA).

Poulter NR, Wedel H, Dahlöf B, Sever PS, Beevers DG, Caulfield M, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J, Pocock S; ASCOT Investigators.

Lancet. 2005 Sep 10-16;366(9489):907-13.

PMID:
16154017
47.

Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial.

Dahlöf B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J; ASCOT Investigators.

Lancet. 2005 Sep 10-16;366(9489):895-906.

PMID:
16154016
48.

Association of renin-angiotensin system gene polymorphisms with antihypertensive responses to angiotensin-converting enzyme inhibition or angiotensin receptor blockade.

Stergiou GS, Efstathiou SP, Inglis GC, Connell JM, McInnes GT, Mountokalakis TD.

J Hum Hypertens. 2005 Dec;19(12):971-4. No abstract available.

PMID:
16049518
49.

Statin administration prior to ischaemic stroke onset and survival: exploratory evidence from matched treatment-control study.

Aslanyan S, Weir CJ, McInnes GT, Reid JL, Walters MR, Lees KR.

Eur J Neurol. 2005 Jul;12(7):493-8.

PMID:
15958087
50.

Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial--lipid-lowering arm (ASCOT-LLA).

Sever PS, Poulter NR, Dahlöf B, Wedel H, Collins R, Beevers G, Caulfield M, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J.

Diabetes Care. 2005 May;28(5):1151-7.

PMID:
15855581

Supplemental Content

Loading ...
Support Center